BACKGROUND: Moderate alcohol consumption has been linked to a decreased risk of cardiovascular death. Systemic inflammation as indicated by elevated levels of C-reactive protein might play a role in this relation. METHODS: To evaluate the association of alcohol consumption with C-reactive protein, we analyzed the findings of the Third National Health and Nutrition Examination, a population-based survey representing the noninstitutionalized US population. Participants were aged 17 and older (n = 11,572). The main outcome measures studied were probability of C-reactive protein measurements being greater than 0.30 mg/dL (corresponding to the 75th percentile for the population) stratified by categories of alcohol consumption. Multivariate logistic regression was used to adjust for potential confounders. RESULTS: Among nondrinkers 31% had elevated C-reactive protein levels, compared with 21% of low-to-moderate-frequency drinkers and 18% of high-frequency drinkers. In a model adjusted for confounding variables, those who drank 1 to 10 times per month (OR 0.83, 95% CI 0.72-0.95), 11 to 30 times (OR 0.74, 95% CI 0.62-0.88), and more than 60 times per month (OR 0.67, 95% CI 0.48-0.93) were less likely than nondrinkers to have elevated C-reactive protein levels. CONCLUSIONS: Alcohol consumption is associated with a decreased probability of elevated C-reactive protein levels. This association supports an anti-inflammatory mechanism by which moderate alcohol use might protect against cardiovascular death.
BACKGROUND: Moderate alcohol consumption has been linked to a decreased risk of cardiovascular death. Systemic inflammation as indicated by elevated levels of C-reactive protein might play a role in this relation. METHODS: To evaluate the association of alcohol consumption with C-reactive protein, we analyzed the findings of the Third National Health and Nutrition Examination, a population-based survey representing the noninstitutionalized US population. Participants were aged 17 and older (n = 11,572). The main outcome measures studied were probability of C-reactive protein measurements being greater than 0.30 mg/dL (corresponding to the 75th percentile for the population) stratified by categories of alcohol consumption. Multivariate logistic regression was used to adjust for potential confounders. RESULTS: Among nondrinkers 31% had elevated C-reactive protein levels, compared with 21% of low-to-moderate-frequency drinkers and 18% of high-frequency drinkers. In a model adjusted for confounding variables, those who drank 1 to 10 times per month (OR 0.83, 95% CI 0.72-0.95), 11 to 30 times (OR 0.74, 95% CI 0.62-0.88), and more than 60 times per month (OR 0.67, 95% CI 0.48-0.93) were less likely than nondrinkers to have elevated C-reactive protein levels. CONCLUSIONS:Alcohol consumption is associated with a decreased probability of elevated C-reactive protein levels. This association supports an anti-inflammatory mechanism by which moderate alcohol use might protect against cardiovascular death.
Authors: Joseph P Coyle; Cressida R Brennan; Shane F Parfrey; Owen J O'Connor; Patrick D Mc Laughlin; Sebastian R Mc Williams; Michael M Maher Journal: Emerg Radiol Date: 2012-04-25
Authors: Sarah E Zemore; Katherine J Karriker-Jaffe; Nina Mulia; William C Kerr; Cindy L Ehlers; Won Kim Cook; Priscilla Martinez; Camillia Lui; Thomas K Greenfield Journal: J Stud Alcohol Drugs Date: 2018-01 Impact factor: 2.582
Authors: Nicole M Heath; Samantha A Chesney; James I Gerhart; Rachel E Goldsmith; Judith L Luborsky; Natalie R Stevens; Stevan E Hobfoll Journal: Cytokine Date: 2013-05-20 Impact factor: 3.861
Authors: Su Yon Jung; Jeanette C Papp; Eric M Sobel; Matteo Pellegrini; Herbert Yu; Zuo-Feng Zhang Journal: Am J Cancer Res Date: 2020-09-01 Impact factor: 6.166
Authors: Su Yon Jung; Herbert Yu; Matteo Pellegrini; Jeanette C Papp; Eric M Sobel; Zuo-Feng Zhang Journal: Am J Cancer Res Date: 2021-04-15 Impact factor: 6.166
Authors: Su Yon Jung; Peter A Scott; Jeanette C Papp; Eric M Sobel; Matteo Pellegrini; Herbert Yu; Sihao Han; Zuo-Feng Zhang Journal: Cancer Prev Res (Phila) Date: 2020-09-14